• Compassionate Use of New Drugs in Children and Adolescents with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Early Experiences and Challenges

      Tadolini, M; Garcia-Prats, AJ; D'Ambrosio, L; Hewison, C; Centis, R; Schaaf, HS; Marais, BJ; Ferreira, H; Caminero, JA; Jonckheere, S; et al. (European Respiratory Society, 2016-06-23)
    • New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

      Harausz, E; Garcia-Prats, A; Seddon, J; Schaaf, H; Hesseling, A; Achar, J; Bernheimer, J; Cruz, A; D'Ambrosio, L; Detjen, A; et al. (American Thoracic Society, 2017-05-15)
      It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.